Literature DB >> 19615885

Nephroureterectomy and segmental ureterectomy in the treatment of invasive upper tract urothelial carcinoma: a population-based study of 2299 patients.

Giovanni Lughezzani1, Claudio Jeldres, Hendrik Isbarn, Maxine Sun, Shahrokh F Shariat, Ahmed Alasker, Daniel Pharand, Hugues Widmer, Philippe Arjane, Markus Graefen, Francesco Montorsi, Paul Perrotte, Pierre I Karakiewicz.   

Abstract

PURPOSE: The TNM staging system represents the cornerstone for classifying patients with upper tract urothelial carcinoma (UTUC). We tested the prognostic impact of pT and pN stages on cancer-specific mortality (CSM) in a large population-based cohort of surgically treated patients with UTUC.
METHODS: Our analyses relied on 2299 patients treated with nephroureterectomy (NU) or segmental ureterectomy (SU) for UTUC within nine Surveillance, Epidemiology and End Results registries between 1988 and 2004. CSM rates after surgery were graphically explored using Kaplan-Meier plots. Univariable and multivariable Cox regression models tested the effect of pT and pN stages on CSM, after adjusting for tumour grade, age, gender, primary tumour location, type and year of surgery.
RESULTS: Five years after surgery, the overall CSM-free survival rate was 77.6%. The 5-year CSM-free survival rates of pT(1)N(0) (n=739), pT(2)N(0) (n=422), pT(3)N(0) (n=691), pT(4)N(0) (n=190) and any T N(1-3) (n=257) were, respectively, 93.5 versus 86.2 versus 64.5 versus 54.7 versus 35.0%. The 5-year CSM-free survival rates of pT(1-2)N(1-3) (n=41) and pT(3-4)N(1-3) (n=216) patients were, respectively, 68.9% and 28.7% (p=0.006). In multivariable analyses, pT and pN stages (p<0.001), as well as tumour grade (p<0.001), achieved independent predictor status. Advanced age adversely affected CSM-free survival (p=0.001). Conversely, tumour location, gender, year and type of surgery did not exert independent predictor status.
CONCLUSION: Durable cancer control can be expected in patients treated with NU or SU for organ-confined (pT(1-2)) UTUC. Conversely, the presence of non-organ-confined (pT(3-4)) disease and/or of nodal metastases (pN(1-3)) exerts a profound detrimental effect on CSM-free survival.

Entities:  

Mesh:

Year:  2009        PMID: 19615885     DOI: 10.1016/j.ejca.2009.06.016

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  30 in total

1.  Combining imaging and ureteroscopy variables in a preoperative multivariable model for prediction of muscle-invasive and non-organ confined disease in patients with upper tract urothelial carcinoma.

Authors:  Ricardo L Favaretto; Shahrokh F Shariat; Caroline Savage; Guilherme Godoy; Daher C Chade; Matthew Kaag; Bernard H Bochner; Jonathan Coleman; Guido Dalbagni
Journal:  BJU Int       Date:  2011-06-01       Impact factor: 5.588

2.  Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration.

Authors:  Douglas G Altman; Lisa M McShane; Willi Sauerbrei; Sheila E Taube
Journal:  BMC Med       Date:  2012-05-29       Impact factor: 8.775

3.  Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration.

Authors:  Douglas G Altman; Lisa M McShane; Willi Sauerbrei; Sheila E Taube
Journal:  PLoS Med       Date:  2012-05-29       Impact factor: 11.069

4.  Oncological and renal outcomes of segmental ureterectomy vs. radical nephroureterectomy for upper tract urothelial carcinoma.

Authors:  Tomonori Kato; Ryo Nakayama; Tomomi Haba; Makoto Kawaguchi; Akira Komiya; Hiroshi Koike
Journal:  Oncol Lett       Date:  2018-09-19       Impact factor: 2.967

5.  Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma.

Authors:  Sima Porten; Arlene O Siefker-Radtke; Lianchun Xiao; Vitaly Margulis; Ashish M Kamat; Christopher G Wood; Eric Jonasch; Colin P N Dinney; Surena F Matin
Journal:  Cancer       Date:  2014-03-13       Impact factor: 6.860

6.  Obesity adversely impacts disease specific outcomes in patients with upper tract urothelial carcinoma.

Authors:  Behfar Ehdaie; Thomas F Chromecki; Richard K Lee; Yair Lotan; Vitaly Margulis; Pierre I Karakiewicz; Giacomo Novara; Jay D Raman; Casey Ng; William T Lowrance; Douglas S Scherr; Shahrokh F Shariat
Journal:  J Urol       Date:  2011-05-14       Impact factor: 7.450

7.  A patient with synchronous bilateral low-grade upper tract urothelial carcinoma who underwent nephroureterectomy and total ureterectomy with ileal ureteric replacement.

Authors:  Yoshinori Matsuda; Takamitsu Inoue; Atsushi Maeno; Atsushi Koizumi; Ryohei Yamamoto; Taketoshi Nara; Sohei Kanda; Kazuyuki Numakura; Mitsuru Saito; Shintaro Narita; Shigeru Satoh; Tomonori Habuchi
Journal:  Int Cancer Conf J       Date:  2020-03-03

8.  Lymph node yield and tumor location in patients with upper tract urothelial carcinoma undergoing nephroureterectomy affects survival: A U.S. population-based analysis (2004-2012).

Authors:  Meera R Chappidi; Max Kates; Michael H Johnson; Noah M Hahn; Trinity J Bivalacqua; Phillip M Pierorazio
Journal:  Urol Oncol       Date:  2016-07-27       Impact factor: 3.498

9.  Urothelial-based reconstructive surgery for upper- and mid-ureteral defects: Long-term results.

Authors:  Barak Rosenzweig; Yoram Mor; Tomer Erlich; Menachem Laufer; Harry Winkler; Issac Kaver; Jacob Ramon; Zohar A Dotan
Journal:  Can Urol Assoc J       Date:  2016-09-13       Impact factor: 1.862

Review 10.  A systematic review and meta-analysis of oncological and renal function outcomes obtained after segmental ureterectomy versus radical nephroureterectomy for upper tract urothelial carcinoma.

Authors:  D Fang; T Seisen; K Yang; P Liu; X Fan; N Singla; G Xiong; L Zhang; X Li; L Zhou
Journal:  Eur J Surg Oncol       Date:  2016-08-25       Impact factor: 4.424

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.